
Immunome is seeking a highly motivated and detail-oriented Associate Scientist, Antibody Sciences to drive our in-house high-throughput (HTP) recombinant protein production efforts, spanning protein expression, purification, and characterization through basic screening in support of rapid, data-driven protein engineering and discovery workflows.
This position will leverage analytical methods including SEC-UPLC, HIC-UPLC, DLS, reduced mass spectrometry, and biolayer interferometry (BLI) to characterize key properties of generated molecules and inform iterative protein engineering.
A key function of this role will be overseeing the integrity and management of Immunome’s recombinant antibody and protein inventory, from intake through material distribution across the organization, enabling efficient iteration and seamless execution across the R&D team.
Responsibilities
Research Design and Execution
Data Analysis and Interpretation
Project Collaboration
Documentation and Reporting
Continuous Learning and Development
Qualifications
Knowledge and Skills
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish)

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.